Gleason Score for Prostate Cancer
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low-Grade Cancer (Grade Group 1)6–6
- Intermediate-Grade Cancer (Grade Group 2-3)7–7
- High-Grade Cancer (Grade Group 4)8–8
- Very High-Grade Cancer (Grade Group 5)9–10
The Gleason Score for Prostate Cancer calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include primary grade. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Histologic grading system for prostate cancer based on microscopic tumor architecture patterns. Uses primary and secondary tumor patterns to predict prognosis and guide treatment decisions. The score combines the two most prevalent architectural patterns found in the tumor specimen.
Clinical Indication
The Gleason Score for Prostate Cancer is indicated for bedside clinical practice to support Histologic grading system for prostate cancer based on microscopic tumor architecture patterns. Uses primary and secondary tumor patterns to predict prognosis and guide treatment decisions. The score combines the two most prevalent architectural patterns found in the tumor specimen.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression. Guideline pearl: Modern ISUP 2014 guidelines have refined grading criteria for greater consistency.
Gleason Score = Primary Grade + Secondary Grade (range 6-10). Grade Groups: GG1=6, GG2=3+4=7, GG3=4+3=7, GG4=8, GG5=9-10
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| primary_grade | integer | Yes | Primary Gleason grade representing the most predominant (>50%) tumor pattern observed microscopically(grade) |
| secondary_grade | integer | Yes | Secondary Gleason grade representing the second most common tumor pattern (at least 5% but <50% of tumor)(grade) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 6–6 | Low-Grade Cancer (Grade Group 1) | Well-differentiated, favorable prognosis |
| 7–7 | Intermediate-Grade Cancer (Grade Group 2-3) | Moderately differentiated, intermediate prognosis |
| 8–8 | High-Grade Cancer (Grade Group 4) | Poorly differentiated, unfavorable prognosis |
| 9–10 | Very High-Grade Cancer (Grade Group 5) | Very poorly differentiated, very unfavorable prognosis |
Evidence-Based References (EBM)
- Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
- Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244-252. doi: 10.1097/PAS.0000000000000530.DOI: 10.1097/PAS.0000000000000530
- Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753-760. doi: 10.1111/j.1464-410X.2012.11611.x.DOI: 10.1111/j.1464-410X.2012.11611.x
- D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974. doi: 10.1001/jama.280.11.969.DOI: 10.1001/jama.280.11.969